Posted by SLS on June 8, 2021, at 20:36:26
In reply to Re: Can some of you sci wizs explain..next gen ap's, posted by alexandra_k on June 8, 2021, at 18:16:31
> They did say that they have reason to believe the dopamine receptor to be involved in the positive symptoms (e.g., delusions, hallucinations, intense affective responses) rather than the negative symptoms (e.g., social withdrawal). So focusing on a particular kind of dopamine receptor is only likely to help with the positive symptoms rather than the negative.
Alexandra, nobody said that risperidone and other antipsychotics didn't have other properties that address negative symptoms - probably 5-HT2a antagonism. However, it is not necessary to block any other type of dopamine receptor other than the D2R to reduce positive symptoms.
The salient point of the article is that you can build an antipsychotic with significantly less liability to produce EPS, yet retain antipsychotic activity. That's all. For some people, this might be incrementally better, but that might be one hell of an increment. We'll see.
Let the doctors and the sufferers decide for themselves whether taking one of these D2R-specific drugs represents something revolutionary or not. How would you evaluate the statistical rate of EPS of these new drugs compared to the older ones? Would you consider it revolutionary to stamp out EPS, TD, and NMS? I would.
If you can find the results of clinical trials examining EPS in these new antipsychotics, it would be great if you could post links to them.
I sometimes have emotional attachments to my guesses, but I prefer to let science come to conclusions - and even then, there is no guarantee that the truth will have been ascertained.
- ScottSome see things as they are and ask why.
I dream of things that never were and ask why not.The only thing necessary for the triumph of evil is that good men do nothing.
poster:SLS
thread:1115429
URL: http://www.dr-bob.org/babble/20210418/msgs/1115486.html